I'm guessing Pfizer is the potential partner . They need new products to replace ones that go ex patent,
Pfizer Oncology division brought in US$12B revenue last year which includes breast cancer drug Ibrance.
MARCH 13 2013 Economic Times
"The drug maker needs more revenue sources in part because it faces the expiration of patents protecting drugs like Ibrance from cheaper competition in the coming years"
I'm guessing Pfizer is the potential partner . They need new...
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $832 | 118.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 9479207 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2715475 | 3 |
View Market Depth
| Last trade - 15.25pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
-0.001 ( 7.14 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.8¢ | 248836 | ||
| Last updated 12.47pm 30/05/2024 ? | |||||
| PAB (ASX) Chart |